文献速递肿瘤 PET/CT核素与放射性配体治疗

乳腺癌SSTR靶向放射诊疗:[68Ga]Ga-DOTATOC与[68Ga]Ga-SSO120同[18F]FDG PET的比较

SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [68Ga]Ga-DOTATOC and [68Ga]Ga-SSO120 with [18F]FDG PET.
PubMed 文献 · J Nucl Med · 2026-09-02

该回顾性单中心研究纳入37例乳腺癌患者,比较SSTR激动剂[68Ga]Ga-DOTATOC与拮抗剂[68Ga]Ga-SSO120 PET,以[18F]FDG PET为参考标准。患者层面SSTR阳性率在ER阳性乳腺癌为80%(16/20)、三阴性乳腺癌为50%(5/10);SSTR显像SUVmax总体低于[18F]FDG,SSTR阳性与进展时间无相关性。

要点

  • ER阳性乳腺癌患者层面SSTR阳性率为80%(16/20),三阴性为50%(5/10)。
  • SSTR显像区域平均SUVmax普遍低于[18F]FDG PET。
  • 仅1例达到Krenning评分3,提示技术上有PRRT资格。

核心结论

  • SSTR可能作为少数晚期转移性ER阳性乳腺癌患者有前景的放射诊疗靶点。
  • 肿瘤摄取多为中度,[68Ga]Ga-DOTATOC与[68Ga]Ga-SSO120之间无实质差异。
  • 对于ER阳性和三阴性乳腺癌的显像,[18F]FDG PET优于[68Ga]Ga-SSTR PET。

研究设计与样本

  • 回顾性单中心研究,纳入2023年2月至2025年2月接受[68Ga]Ga-DOTATOC或[68Ga]Ga-SSO120 PET的乳腺癌患者。
  • 所有患者均行[18F]FDG PET并作为参考标准。
  • 共识别37例乳腺癌患者(26例ER阳性,11例三阴性),排除7例无可检测肿瘤后最终分析30例。
  • [68Ga]Ga-DOTATOC平均给药活度88 MBq、摄取时间64 min;[68Ga]Ga-SSO120平均给药活度131 MBq、摄取时间66 min。

主要发现

  • 患者层面SSTR阳性(≥1个病灶)在ER阳性乳腺癌为80%(16/20),在三阴性乳腺癌为50%(5/10)。
  • ER阳性疾病中,[68Ga]Ga-DOTATOC阳性率85%、[68Ga]Ga-SSO120阳性率71%;三阴性乳腺癌中仅观察到[68Ga]Ga-DOTATOC阳性(83%)。
  • 区域层面,ER阳性乳腺癌中60%(31/52)的[18F]FDG阳性区域为SSTR阳性,三阴性乳腺癌中为33%(7/21)。
  • 区域平均SUVmax:ER阳性乳腺癌中[68Ga]Ga-DOTATOC vs [18F]FDG为7.2 ± 3.4 vs 9.3 ± 4.3,[68Ga]Ga-SSO120 vs [18F]FDG为4.5 ± 1.4 vs 8.1 ± 3.2;三阴性乳腺癌中[68Ga]Ga-DOTATOC vs [18F]FDG为4.1 ± 0.6 vs 19.8 ± 3.3,三阴性患者未见[68Ga]Ga-SSO120摄取。
  • 1例患者达到Krenning评分3,提示技术上有资格接受肽受体放射性核素治疗;SSTR阳性与进展时间无相关性。

关键数值与推荐

  • SSTR阳性定义为至少1个病灶在SSTR PET上阳性。
  • Krenning评分3分提示技术上有资格接受肽受体放射性核素治疗。

临床怎么用

  • 在晚期转移性ER阳性乳腺癌中可考虑SSTR PET评估放射诊疗靶点,但[18F]FDG PET在显像上更优。
  • 三阴性乳腺癌中[68Ga]Ga-SSO120未见摄取,SSTR显像阳性主要见于[68Ga]Ga-DOTATOC。
  • SSTR阳性与进展时间无相关性,不能用于预后分层。

局限性

  • 回顾性单中心设计,最终分析仅30例患者,样本量小。
  • 排除7例无可检测肿瘤患者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Somatostatin receptor (SSTR)-targeting radiotracers hold promise for theranostic applications in breast cancer (BC). This retrospective single-center study aimed to assess the proportion of SSTR-positive BC and its relevance for peptide receptor radionuclide therapy. SSTR-agonist- and SSTR-antagonist-based PET tracers are compared. Methods: Patients with BC who underwent PET imaging with SSTR agonist [68Ga]Ga-DOTATOC or SSTR antagonist [68Ga]Ga-SSO120 (February 2023 to February 2025) for initial or follow-up staging were included. All patients underwent [18F]FDG PET, which was used as the reference standard. Mean administered activities and uptake times were 88 MBq for 64 min with [68Ga]Ga-DOTATOC and 131 MBq for 66 min with [68Ga]Ga-SSO120, respectively. PET-positive lesions were reported in 6 anatomic categories. Tumors were segmented; SUVs, tumor-to-liver ratios, and tumor volumes were calculated. Time to progression stratified by SSTR expression was assessed using the log-rank test. Results: In total, 37 patients with BC (26 estrogen-receptor [ER]-positive, 11 triple negative [TN]) were identified; final analysis was limited to 30 patients after excluding 7 with no detectable tumor. Most had metastatic disease (M1) at staging (26/36). On the patient level, SSTR-positive tumor (≥1 lesion) was detected in 80% of ER-positive BC (16/20) and in 50% of patients with TNBC (5/10). In ER-positive disease, positivity was comparable for [68Ga]Ga-DOTATOC (85%) and [68Ga]Ga-SSO120 (71%), whereas in TNBC, positivity was observed with [68Ga]Ga-DOTATOC (83%) only. On the region level, 60% (31/52) of [18F]FDG-positive regions in ER-positive BC and 33% (7/21) in TNBC were SSTR-positive. Region-based mean SUVmax was generally lower with SSTR imaging: 7.2 ± 3.4 versus 9.3 ± 4.3 ([68Ga]Ga-DOTATOC vs. [18F]FDG) and 4.5 ± 1.4 versus 8.1 ± 3.2 ([68Ga]Ga-SSO120 vs. [18F]FDG) in ER-positive BC and 4.1 ± 0.6 versus 19.8 ± 3.3 ([68Ga]Ga-DOTATOC vs. [18F]FDG), with absent [68Ga]Ga-SSO120 uptake in patients with TNBC. One patient reached a Krenning score of 3, indicating technical eligibility for peptide receptor radionuclide therapy. SSTR positivity did not correlate with time to progression. Conclusion: SSTR may serve as a promising radiotheranostic target in a small subset of patients with advanced metastatic ER-positive BC. Tumor uptake was mostly moderate, without substantial difference between [68Ga]Ga-DOTATOC and [68Ga]Ga-SSO120. For imaging, [18F]FDG PET outperformed [68Ga]Ga-SSTR PET in patients with ER-positive BC and TNBC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Küper AT, Shiyam Sundar LK, Djaileb L, et al. SSTR-Targeted Radiotheranostics in Breast Cancer: A Comparison of [68Ga]Ga-DOTATOC and [68Ga]Ga-SSO120 with [18F]FDG PET. J Nucl Med. 2026. PMID: 42350034. doi:10.2967/jnumed.126.272521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。